NAUT vs. LAB, EYPT, AEHR, SENS, ALNT, QTRX, QSI, KEQU, FEIM, and AKYA
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Senseonics (SENS), Allient (ALNT), Quanterix (QTRX), Quantum-Si (QSI), Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), and Akoya Biosciences (AKYA). These companies are all part of the "measuring and control equipment" industry.
Nautilus Biotechnology vs.
Standard BioTools (NASDAQ:LAB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, Standard BioTools had 8 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 11 mentions for Standard BioTools and 3 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.96 beat Standard BioTools' score of 0.30 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.
53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 53.1% of Standard BioTools shares are owned by company insiders. Comparatively, 40.5% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Nautilus Biotechnology has a net margin of 0.00% compared to Standard BioTools' net margin of -79.92%. Standard BioTools' return on equity of -27.05% beat Nautilus Biotechnology's return on equity.
Standard BioTools currently has a consensus price target of $2.88, indicating a potential upside of 66.18%. Nautilus Biotechnology has a consensus price target of $3.58, indicating a potential upside of 88.60%. Given Nautilus Biotechnology's higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Standard BioTools.
Standard BioTools has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Standard BioTools received 1 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 100.00% of users gave Standard BioTools an outperform vote while only 19.05% of users gave Nautilus Biotechnology an outperform vote.
Nautilus Biotechnology has lower revenue, but higher earnings than Standard BioTools. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Summary
Standard BioTools beats Nautilus Biotechnology on 12 of the 17 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:NAUT) was last updated on 1/16/2025 by MarketBeat.com Staff
